Healthcare >> CEO Interviews >> October 17, 2003
DAVID G. NANCE is President, Chief Executive Officer and a member of the
Board of Directors of Introgen Therapeutics, Inc. Introgen, a leader in
the development of biopharmaceutical products with an oncology focus,
was founded by Mr. Nance in 1993. Prior to founding Introgen, Mr. Nance
was Managing Partner of Texas Biomedical Development Partners, a
healthcare investment and startup management firm. The partners of TBDP
have been involved in the formation of numerous biomedical and
technology companies including biologics, diagnostics, drug development
and marketing, vaccines, fine chemicals, medical devices, nutrition,
agri-biotech and veterinary medicine, robotic surgery, health care
services, bioinformatics and genomics, gene therapies, software, applied
materials, industrial manufacturing and information technologies. Mr.
Nance has testified before the Joint U.S. Congressional Task Force on
Science, Healthcare and the Economy, the U.S. Senate and U.S. House of
Representatives and the NIH. He has also testified before the Texas
Senate and Texas House of Representatives. In 1999, the David G. and
Christy M. Nance Laboratory for Gene Therapy Research was established at
M. D. Anderson Cancer Center. Mr. Nance has served, or currently serves,
as a Director on a number of corporate, charitable and public Boards. Profile
products?
Mr. Nance: Introgen is a late stage oncology company focusing on
biologics with novel mechanisms of action to
